19933-22-3

Usage

Uses

Used in Pharmaceutical Industry:
1-phenylpyrazolidine-3,5-dione is used as an anti-inflammatory and analgesic agent for the treatment of conditions such as arthritis and gout, due to its ability to inhibit prostaglandin production, thereby reducing pain and inflammation.
Used in Pain Management:
1-phenylpyrazolidine-3,5-dione serves as a pain reliever, particularly for inflammatory conditions, by targeting the biochemical pathways that lead to discomfort and swelling.
Despite its efficacy, the use of 1-phenylpyrazolidine-3,5-dione is cautioned due to its association with several adverse effects, which has led to its limited prescription and preference for alternative treatments with fewer side effects.

InChI:InChI=1/C9H8N2O2/c12-8-6-9(13)11(10-8)7-4-2-1-3-5-7/h1-5H,6H2,(H,10,12)

Upstream product

• 70373-98-7 5-amino-1-phenyl-1H-pyrazol-3(2H)-one 
• 4149-06-8 3-amino-1-phenyl-2-pyrazolin-5-one 
• 14064-10-9 diethyl 2-chloromalonate 
• 100-63-0 phenylhydrazine 
• 504-64-3 carbon suboxide 
• 141-52-6 sodium ethanolate 
• 105-53-3 diethyl malonate 
• 141-82-2 malonic acid 
• 114-83-0 1-acetyl-2-phenylhydrazine 
• 140862-02-8 phenyl-pyrazolidinetrione-4-oxime 
• 60598-59-6 cyanoacetic acid N-phenylhydrazide 
• 15083-26-8 4-benzylidene-1-phenyl-3,5-pyrazolidinedione 
• 4599-10-4 4-(4'-nitrobenzylidene)-1-phenyl-3,5-pyrazolidinedione 
• 36239-09-5 ethyl chlorocarbonylacetate 

Downstream Products

• 103162-21-6 1-phenyl-4-trityl-pyrazolidine-3,5-dione 
• 21272-26-4 phenyl-pyrazolidinetrione 4-phenylhydrazone 
• 15083-26-8 4-benzylidene-1-phenyl-3,5-pyrazolidinedione 
• 87059-94-7 4-(4-methoxybenzyliden)-1-phenyl-3,5-dioxypyrazolidine 
• 101117-88-8 3,5-dioxo-2-phenyl-pyrazolidine-1-carboxylic acid anilide 
• 101424-33-3 3,5-dioxo-2-phenyl-pyrazolidine-1-carboxylic acid cyclohexylamide 
• 353287-29-3 1-phenyl-3.5-dioxo-4-phenyliminomethyl-pyrazolidine 
• 4599-40-0 malonic acid-(N-phenyl-hydrazide)-(N'-phenyl-hydrazide) 
• 87343-68-8 1-phenyl-4-isopropylidenepyrazolidine-3,5-dione 
• 109511-38-8 3,5-dioxo-2-phenyl-pyrazolidine-1-carboxylic acid 4-ethoxy-anilide 
• 109408-86-8 5-dimethylcarbamoyloxy-3-oxo-2-phenyl-2,3-dihydro-pyrazole-1-carboxylic acid dimethylamide 
• 62214-48-6 1,4,4-trimethyl-2-phenyl-pyrazolidine-3,5-dione 
• 51039-42-0 1-phenyl-3,5-dichloropyrazole 
• 51039-44-2 3,5-dibromo-1-phenyl-1H-pyrazole 

Relevant academic research and scientific papers

Blockade of inflammatory responses by a small-molecule inhibitor of the Rac activator DOCK2

Tissue infiltration of activated lymphocytes is a hallmark of transplant rejection and organ-specific autoimmune diseases. Migration and activation of lymphocytes depend on DOCK2, an atypical Rac activator predominantly expressed in hematopoietic cells. Although DOCK2 does not contain Dbl homology domain typically found in guanine nucleotide exchange factors, DOCK2 mediates the GTP-GDP exchange reaction for Rac through its DHR-2 domain. Here, we have identified 4-[3′-(2″-chlorophenyl)-2′-propen-1′-ylidene] -1-phenyl-3,5-pyrazolidinedione (CPYPP) as a small-molecule inhibitor of DOCK2. CPYPP bound to DOCK2 DHR-2 domain in a reversible manner and inhibited its catalytic activity in vitro. When lymphocytes were treated with CPYPP, both chemokine receptor- and antigen receptor-mediated Rac activation were blocked, resulting in marked reduction of chemotactic response and T cell activation. These results provide a rational of and a chemical scaffold for development of the DOCK2-targeting immunosuppressant.

1,3-Dipolar cycloaddition approach to novel dispiro[pyrazolidine-4,3'- pyrrolizidine-2',3 -indoline]-2 ,3,5-triones

A simple and convenient 1,3-dipolar cycloaddition of non-stabilised azomethine ylides derived from isatins and L-proline, in a variety of different solvents, to (Z)-4-arylidene-1-phenylpyrazolidine-3,5-diones as dipolarophiles afforded a series of novel dispiro[pyrazolidine- 4,3'-pyrrolizidine-2',3 -indoline]-2 ,3,5-triones regioselectively and in good yields.

Green synthetic investigation and spectral characterization of some spiro pyrazolidine-based heterocycles with potential biological activity

A green, rapid, and efficient methodology is developed for the synthesis of 1-phenyl-3,5-pyrazolidinedione (3) by the reaction of malonic acid with phenyl hydrazine in the presence of phosphorous oxychloride under solvent-free conditions. The later compou

PYRAZOLONE DERIVATIVES AS NITROXYL DONORS

The disclosed subject matter provides pyrazolone derivative compounds, pharmaceutical compositions comprising such compounds, kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the disclosed subject matter provides methods of using such compounds or pharmaceutical compositions for treating heart failure.

Regioselective synthesis and anti-inflammatory activity of novel dispiro[pyrazolidine-4,3′-pyrrolidine-2′,3″-indoline] -2″,3,5-triones

Novel dispiro[pyrazolidine-4,3′-pyrrolidine-2′,3″- indoline]-2″,3,5-triones 5a-j were obtained regioselectively by 1,3-dipolar cycloaddition reaction of 4-arylidene-1-phenylpyrazolidine-3,5- diones 2a-e as dipolarophiles with non-stabilized azomethine yli

Simple route to a novel class of pyrazolidine-3,5-dione based azo dyes

We report an easiest synthesis strategy of a new class of synthetic dyes by coupling of functionalized pyrazolidine-3,5-dione derivatives via diazotization reaction with aromatic diamine for the azoic dyes or via dimerization reaction to synthesize the H chromophore dyes. Electron delocalization between the two coupled components has been studied using UV-vis spectroscopy, infrared, and NMR spectroscopy. In addition, the formation mechanism of such compounds has been discussed.

Reactions of 4-alkylidene (arylidene)-1-phenylpyrazolidine-3,5-dione

Reactions of 4-alkylidene(arylidene)-1-phenylpyrazolidine-3,5-dione with oxidizing (chromium trioxide/acetic acid) as well as with reducing (sodium borohydride/methanol) agents were carried out. Phenylhydrazine reacted with 4-arylidene-1-phenylpyrazolidine-3,5-diones via fission of exo C=C bond to give 1-phenylpyrazolidine-3,5-dione and the corresponding aryl hydrazones.

PYRAZOLIDINEDIONE DERIVATIVES AND THEIR USE AS PLATELET AGGREGATION INHIBITORS

Pyrazolidinedione derivatives of the general formula (I), wherein R1 is hydrogen, optionally substituted alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl; and R2 is aryl or heteroaryl; tautomers thereof; geometric is

2-(pyrazol-5-yl-oxymethyl)-1,2-benzisothiazol-3 (2H)-One 1, 1-dioxides and compositions and method of use thereof

2-(Pyrazol-5-yl-oxymethyl)-1,2-benzisothiazol-3(2H)-one 1,1-dioxides, pharmaceutical compositions containing them and methods for the treatment of degenerative diseases utilizing them.